Chronic Kidney Disease is a silent killer that progresses gradually, often going unnoticed until the late stages. While ...

Weight loss drugs like Ozempic deliver more health benefits than expected.

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

While Metformin continues to be the standard first-line treatment for Type-2 diabetes, newer therapies such as SGLT2 ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

G LP-1 drugs containing semaglutide (the active ingredient in Ozempic and Wegovy) have exploded in popularity for their ...

Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.